An ongoing single-arm, open-label, single-center phase-II trial aims to evaluate the clinical feasibility and safety of neoadjuvant sintilimab plus chemotherapy in patients with EGFR-mutated stage IIB–IIIB NSCLC (NEOTIDE, NCT05244213). Here, EGFR is linked to non-small cell lung carcinoma.